NASA has awarded Redwire Corporation an additional $4 million to support new drug development investigations on the International Space Station (ISS) using the company’s PIL‑BOX technology. The funding expands an existing task order under a $25 million, five‑year indefinite‑delivery/indefinite‑quantity (IDIQ) contract that was first awarded in August 2025.
The award increases the scope of the task order that covers on‑orbit operations and biotechnology facilities on the ISS. By adding $4 million, Redwire can accelerate research into pharmaceuticals that benefit from microgravity, a niche that has attracted partners such as Aspera Biomedicines, Bristol Myers Squibb, and Eli Lilly. The expanded contract also boosts Redwire’s backlog to a record $411.2 million at the end of 2025, underscoring the company’s growing pipeline of space‑based projects.
Redwire’s most recent quarterly results, released on March 10 2026, showed revenue of $108.79 million for Q4 2025—up 10.3 % year‑over‑year and beating analyst expectations of $98.77 million. The company missed earnings per share, reporting –$0.58 versus an estimate of –$0.16. The revenue beat was driven by strong demand in the core SpaceMD segment, while the EPS miss reflected negative EBITDA and one‑time charges associated with scaling the new contract work.
SpaceMD, which was formed on August 4 2025, is the division that commercializes pharmaceutical drug development in space. The new NASA award provides a direct revenue source for SpaceMD and signals that the division’s technology—PIL‑BOX, a proven microgravity crystallization platform—has reached a level of maturity that attracts federal funding. The award also positions SpaceMD to pursue additional contracts and licensing opportunities with major pharmaceutical partners.
Mike Gold, President of Redwire’s Space business segment, said, “The space and pharmaceutical industries are coming together in a way that will transform both fields. NASA and the InSPA program are playing a critical role by acting as a catalyst for revolutionary new public and private sector capabilities, and we’re proud and grateful that they have selected Redwire to implement this work tackling diseases ranging from cancer to osteoporosis and obesity. By going to space, together with our NASA partners, we can improve life on Earth.”
The announcement was welcomed by investors and analysts, who highlighted the award as a positive development for Redwire’s space‑based drug development strategy and its broader move toward commercializing microgravity research.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.